Clinical Trial Update: A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 [NA]

View source ↗

Summary

A 26-week extension study evaluating biological and functional changes in healthy smokers after switching to THS 2.2; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoking

Drugs mentioned

• THS 2.2 (tobacco heated product variant)

Snippet

Sponsor: Philip Morris Products S.A. | Conditions: Smoking | NA | Status: COMPLETED | Results posted: 2020-12-04